Tal y como hemos realizado con congresos previos, a lo largo de la celebración del Congreso Europeo de Cardiología (París, 27 a 31 de Agosto) comentaremos en el blog los principales resultados de los ensayos clínicos más importantes.
Nos centraremos en los siguientes:
Hot Line I – Riesgo cardiovascular y complicaciones
28 Agosto 2011, 11:00-12:30
PURE: The prevention gaps in 17 low, middle and high income countries involving over 150,000 people
HCS: Prospective evaluation of post-prandial triglycerides and cardiovascular events in patients with coronary artery disease
dal-VESSEL: Efficacy and safety of dalcetrapib in patients with or at risk of coronary heart disease
ARISTOTLE: Efficacy and safety of Apixaban compared to Warfarin for prevention of stroke and systemic embolism in 18,202 patients with atrial fibrillation: primary results of the ARISTOTLE trial
CORP: COlchicine for Recurrent Pericarditis (CORP). A multicenter, double-blind, randomized, controlled trial
Hot Line II – Tratamientos
29 Agosto 2011, 11:00-12:30
EVATEL: Remote follow-up of patients implanted with an ICD: the prospective randomized EVATEL study
ECOST: Safety of implantable cardioverter defibrillator follow-up using remote monitoring: a randomized controlled trial
EMPHASIS-HF: The effect of eplerenone versus placebo on cardiovascular mortality or heart failure hospitalization in subjects with NYHA class II chronic systolic heart failure: An analysis of the High-risk groups in the study population
RESET: One-year outcome of the Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial
Comparison of three-year outcome after PCI and CABG stratified by the SYNTAX score in patients with triple vessel coronary artery disease: an observation from the CREDO-Kyoto PCI/CABG registry Cohort-2
Hot Line III – Síndromes coronarios agudos
30 Agosto 2011, 11:00-12:30
PRODIGY: Randomized comparison of six versus twenty-four months clopidogrel therapy after balancing anti-intimal hyperplasia stent potency in all comer patients undergoing percutaneous coronary intervention
The RUBY-1 trial: safety, tolerability and efficacy of YM150, an oral factor Xa inhibitor, in secondary prevention of ischaemic vascular events in patients following a acute coronary syndrome
EXAMINATION: A randomized comparison between everolimus-eluting stent and bare metal stent in patients with ST-segment elevation myocardial infarction
Newer generation everolimus-eluting stents eliminate the risk of very late stent thrombosis compared with early generation sirolimus-eluting and paclitaxel-eluting stents
CRISP AMI: A multi-center, randomized, controlled study of mechanical left ventricular unloading with Counterpulsation to Reduce Infarct size pre-PCI for Acute Myocardial Infarction: rationale and design of the CRISP AMI trial
